There are also now two drugs on the market that are FDA-approved for weight loss -- Wegovy, a medication that contains the same main ingredient, semaglutide, as Ozempic, and Zepbound, a medication that contains the same main ingredient, tirzepatide, as Mounjaro
Standard and mannitol-free formulations are offered where shown in the variation selector
Retatrutide represents the current frontier in incretin pharmacology a single 39-amino-acid synthetic peptide that simultaneously activates three metabolic receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon
They are comparing a real option today with one that might be available in the future
The pilot program will also end in December 2027